Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)

  • Etude concernée: IFCT-1601
  • Auteurs / Authors: Wislez M, Mazieres J, Lavole A, Zalcman G, Carre O, Egenod T, Caliandro R, Dubos-Arvis C, Jeannin G, Molinier O, Massiani MA, Langlais A, Morin F, Le Pimpec Barthes F, Brouchet L, Assouad J, Milleron B, Damotte D, Antoine M, Westeel V
  • Journal / Conference: The Journal for Immunotherapy of Cancer
  • Année / Year: 2022
  • PMID: 36270733
  • Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/36270733/
  • PDF: e005636.full.pdf